Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · LINCOLN

LINCOLN

HealthcarePharmaceuticals & Biotechnology₹1029 cr market cap
₹514.45 ▲ +0.0% today As of 19 Nov 2026
52-week low ₹444.2052-week high ₹758.15

-32.1% from the 52-week high · +15.8% above the low

Lincoln Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat and currently employs 1,700 full-time employees. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid in bott, liquid injection and pharma products. The company has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The firm serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The firm's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.

The short version. LINCOLN reported revenue of ₹191 crore for Sep 2026, up 17.2% from a year earlier. Net profit was ₹20 crore (up 0.0% year on year). Return on equity was 11.6% in Mar 2026. Promoter holding was 49.78% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

LINCOLN trades 32.1% below its 52-week high and 15.8% above its 52-week low.

Change over period: —

1M-3.9%
3M-15.6%
6M-27.0%
1Y-3.7%

2 · The business

Is it growing?

Sales, year on year+17.2%

Sep 2026 revenue of ₹191 cr.

Profit, year on year+0.0%

Sep 2026 net profit of ₹20 cr.

Net margin10.7%

1.5 pts lower than a year earlier.

3-year growth6.4% profit

Revenue compounded at 9.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue191177187166163154168147
Net profit2036122920281221
Net margin %10.720.46.217.212.218.06.914.2
EPS (₹)10.218.095.8114.289.9813.825.7810.37

Annual

FY2026FY2025FY2024FY2023FY2022FY2018
Revenue671623581510472362
Net profit888293736935
Net margin %13.113.216.114.314.79.6
EPS (₹)43.8841.1146.5836.434.6317.31

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.6% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.612.315.714.5
Return on capital %15.016.120.319.9
EBITDA margin %18.619.221.821.0
Net margin %12.512.815.213.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.8%—
Profit CAGR6.4%—
Debt to equity0.01
Interest cover115.1x
Current ratio5.25
P/E ratio10.6

4 · The owners

Who holds it, and are they adding?

Promoter holding49.78%

Unchanged over 8 quarters.

Foreign institutions4.55%

Down 0.61 pts over 8 quarters.

Domestic institutions0.02%

Up 0.02 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter49.7849.7849.7849.7849.7849.7849.7849.780.0
FII5.165.05.144.724.75.194.64.55-0.61
DII00.010.010.010.011.090.270.02+0.02
Public45.0645.2245.0745.4945.5243.9445.3645.65+0.59

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.03% of NAV
  • Bandhan BSE Healthcare Index Fund0.03% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for LINCOLN are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about LINCOLN

What is the LINCOLN share price?

LINCOLN (LINCOLN) last closed at ₹514.45, up 0.0% on the day. Its 52-week range is ₹444.20 to ₹758.15.

What is the market cap of LINCOLN?

LINCOLN has a market capitalisation of about ₹1,029 crore. Its price-to-earnings ratio is 10.6.

How are LINCOLN's latest results?

LINCOLN reported revenue of ₹191 crore for Sep 2026, up 17.2% from a year earlier. Net profit was ₹20 crore (up 0.0% year on year). Return on equity was 11.6% in Mar 2026. Promoter holding was 49.78% in Sep 2026, up 0.00 points over 8 quarters.

Who owns LINCOLN?

As of Sep 2026, shareholding was: Promoter 49.78%, FII 4.55%, DII 0.02%, Public 45.65%.

How many mutual funds hold LINCOLN?

2 mutual fund schemes held LINCOLN in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 12 Sep 2025 · Final Dividend - Rs. 1.8
  • 13 Sep 2024 · Final Dividend - Rs. 1.8
  • 15 Sep 2023 · Dividend - Rs. 1.5
  • 15 Sep 2022 · Dividend - Rs. 1.5
  • 16 Sep 2021 · Dividend - Rs. 1.5
  • 05 Mar 2020 · Interim Dividend - Rs. 1.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.